

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/851,873		
		Filing Date	5-08-01		
		First Named Inventor	Rolf F. Kletzien		
		Art Unit	1646		
		Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	28341/00233

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
RH	C1	Bitko, <i>et al.</i> , "An endoplasmic reticulum-specific stress-activated caspase (caspase-12) is implicated in the apoptosis of A549 epithelial cells by respiratory syncytial virus," <i>J. Cell. Biochem.</i> 80:441-454 (2001).		
	C2	Celesia, "Disorders of membrane channels or channelopathies," <i>Clin. Neurophysiol.</i> 112:2-18 (2001).		
	C3	Deigner, <i>et al.</i> , "Apoptosis modulators in the therapy of neurodegenerative diseases," <i>Exp. Opin. Investig. Drugs</i> 9:747-764 (2000).		
	C4	Kaufman, "Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls," <i>Genes & Develop.</i> 13:1211-1233 (1999).		
	C5	Kumar, "Mechanisms mediating caspase activation in cell death," <i>Cell Death Differ.</i> 6:1060-1066 (1999).		
RH	C6	Nakagawa, <i>et al.</i> , "Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid- β ," <i>Nature</i> 403:98-103 (2000).		
RH	C7	NCBI Database Genbank Accession No. AC009795, National Library of Medicine, (Bethesda, Maryland, US).		
RH	C8	NCBI Database Genbank Accession No. AC009799, National Library of Medicine, (Bethesda, Maryland, US).		
RH	C9	NCBI Database Genbank Accession No. AP002004, National Library of Medicine, (Bethesda, Maryland, US).		
RH	C10	Paschen, "Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different		


[Signature] 12/24/02

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/851,873
				Filing Date	5-08-01
				First Named Inventor	Rolf F. Kletzien
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	28341/00233

		pathological states," <i>Cell Calcium</i> 29:1-11 (2001).
RP	C11	Scaffidi, <i>et al.</i> , "FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b," <i>J. Biol. Chem.</i> 272:26953-26958 (1997).
	C12	Shorofsky, <i>et al.</i> , "Calcium currents and arrhythmias: insights from molecular biology," <i>Am. J. Med.</i> 110:127-140 (2001).
	C13	Slee, <i>et al.</i> , "Serial killers: ordering caspase activation events in apoptosis," <i>Cell Death Differ.</i> 6:1067-1074 (1999).
	C14	Stennicke, <i>et al.</i> , "Catalytic properties of the caspases," <i>Cell Death Differ.</i> 6:1054-1059 (1999).
	C15	Takahashi, "Caspase: executioner and undertaker of apoptosis," <i>Int. J. Hematology</i> 70:226-232 (1999).
	C16	Tzivoni, "End organ protection by calcium-channel blockers," <i>Clin. Cardiol.</i> 24:102-106 (2001).
	C17	Van de Craen, <i>et al.</i> , "Characterization of seven murine caspase family members," <i>FEBS Lett.</i> 403:61-69 (1997).
	C18	Vanderkish, <i>et al.</i> , "The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states," <i>Int. J. Exp. Path.</i> 81:323-339 (2000).
	C19	Yoneda, <i>et al.</i> , "Activation of caspase-12, an endoplasmic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2 (TRAF2) dependent mechanism in response to ER stress," <i>J. Biol. Chem.</i> , Manuscript M010677200, January 29, 2001.
RP	C20	Zeuner, <i>et al.</i> , "Caspase activation without death," <i>Cell Death Differ.</i> 6:1075-1080 (1999).

Examiner Signature		Date Considered	12/20/02
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).